Annual Secretarial Compliance Report for the year ended March 31, 2025
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Drugs filed its Annual Secretarial Compliance Report for FY25, confirming overall compliance with SEBI regulations, with a few exceptions flagged by the Practising Company Secretary. The company delayed intimation of a Maharashtra Pollution Control Board (MPCB) Voluntary Closure Direction dated July 13, 2024 for its T-150 unit at Tarapur, notifying stock exchanges on July 17, 2024 (4 days late), which prompted a cautionary letter from BSE and NSE on April 1, 2025; no fine was levied. Non-executive director Mr. Narendra Salvi inadvertently executed a contra trade of 500 equity shares on December 24 and 27, 2024, with the resulting profit of Rs 11,181 disgorged to SEBI's Investor Protection and Education Fund on March 17, 2025. Separately, SEBI issued an administrative warning letter to the Compliance Officer on March 4, 2025 for not obtaining immediate relative details of designated persons under PIT Regulations.
The compliance lapses are relatively minor with no monetary penalties, but the MPCB closure of the Tarapur unit, combined with the SEBI warning on insider trading controls, signals governance and environmental oversight concerns that shareholders should monitor closely.